Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
---|
02/28/2013 | WO2012145509A3 Adeno-associated-virus rep sequences, vectors, and viruses |
02/28/2013 | WO2012142434A3 Aav mediated ctla-4 gene transfer to treat sjogren's syndrome |
02/28/2013 | WO2012139068A9 Co-administration of arsenic compounds and anti-herpes virus anti-virals |
02/28/2013 | WO2012127379A3 A method for the analysis of the evolution of gene sequences and for the forecast of an emerging viral strain |
02/28/2013 | WO2012125525A3 Equine rhinitis vaccine |
02/28/2013 | WO2012007728A8 Method for producing toxoids using alpha - dicarbonyl compounds |
02/28/2013 | WO2007025388A9 Anti-apoptotic protein antibodies |
02/28/2013 | US20130052667 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
02/28/2013 | US20130052237 Methods of Manufacturing Viscous Liquid Pharmaceutical Formulations |
02/28/2013 | US20130052235 Herpes simplex virus nanoemulsion vaccine |
02/28/2013 | US20130052230 Salmonella vaccine |
02/28/2013 | US20130052229 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
02/28/2013 | US20130052228 Attenuated fish vaccine following culture in iron limited media |
02/28/2013 | US20130052227 Hyperblebbing shigella strains |
02/28/2013 | US20130052226 Compositions and methods for preventing or treating a human parvovirus infection |
02/28/2013 | US20130052225 Infectious dna vaccines against chikungunya virus |
02/28/2013 | US20130052224 Production of poliovirus at high titers for vaccine production |
02/28/2013 | US20130052223 Universal vaccine against h5n1 lineages |
02/28/2013 | US20130052222 Influenza nucleic acid molecules and vaccines made therefrom |
02/28/2013 | US20130052221 Dna-protein vaccination protocols |
02/28/2013 | US20130052220 Yeast-hiv antigen compositions and methods of using the same |
02/28/2013 | US20130052219 Preparation method of virus expressing alpha-galactose epitope and vaccine |
02/28/2013 | US20130052218 Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions |
02/28/2013 | US20130052217 Tumor vaccination involving a humoral immune response against self-proteins |
02/28/2013 | US20130052216 Targeted heterologous antigen presentation on calicivirus virus-like particles |
02/28/2013 | US20130052215 Tumor vaccine |
02/28/2013 | US20130052214 Identification of a peptide(s) that induces autoimmune anterior uveitis |
02/28/2013 | US20130052213 Novel immunomodulatory peptide |
02/28/2013 | US20130052212 Method for allogeneic cell therapy |
02/28/2013 | US20130052211 Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof |
02/28/2013 | US20130052210 Use of ccl1 in therapy |
02/28/2013 | US20130052209 Protein drug formulations and packages |
02/28/2013 | US20130052208 Process for Preparing an Immunoglobulin Composition |
02/28/2013 | US20130052207 Prognostic Method for Pulmonary Adenocarcinoma, Pulmonary Adenocarcinoma Detection Kit, and Pharmaceutical Composition for Treating Pulmonary Adenocarcinoma |
02/28/2013 | US20130052206 Prognostic Marker For Cryoglobulinemic Vasculitis And B Cell Malignancies In HCV Infected Patients |
02/28/2013 | US20130052205 Flt3 receptor antagonists for the treatment or the prevention of pain disorders |
02/28/2013 | US20130052204 (poly)-glycerolphosphate-based anti-gram positive bacterial vaccine |
02/28/2013 | US20130052203 In vivo screening models for treatment of qc-related disorders |
02/28/2013 | US20130052202 HIGH AFFINITY, ANTI-HUMAN IgE ANTIBODIES |
02/28/2013 | US20130052201 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
02/28/2013 | US20130052200 Naturally occurring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
02/28/2013 | US20130052199 Molecular Determinants of Myeloma Bone Disease and Uses Thereof |
02/28/2013 | US20130052198 Anti-inflammatory factors |
02/28/2013 | US20130052197 Novel anti-cd98 antibody and use thereof |
02/28/2013 | US20130052196 Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
02/28/2013 | US20130052195 Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof |
02/28/2013 | US20130052194 Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same |
02/28/2013 | US20130052193 CONTROLLING ALLERGY AND ASTHMA BY ACTIVATING HUMAN DCs VIA DECTIN-1 OR TOLL-LIKE RECEPTOR 2 (TLR2) |
02/28/2013 | US20130052192 Activatable Constructs |
02/28/2013 | US20130052191 Anti-alpha2 integrin antibodies and their uses |
02/28/2013 | US20130052190 CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
02/28/2013 | US20130052189 Method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities |
02/28/2013 | US20130052188 Systems and methods for obtaining immunoglobulin from blood |
02/28/2013 | US20130052187 Antibodies Directed Against Hepatitis C Virus E1E2 Complex, Compositions of HCV Particles, and Pharmaceutical Compositions |
02/28/2013 | US20130052186 Plasma Carboxypeptidase B as a Predictor for Disease Severity and Response |
02/28/2013 | US20130052163 Human Rhinovirus (HRV) Antibodies |
02/28/2013 | US20130052159 Methods for treatment of microbial disorders |
02/28/2013 | US20130052135 Molecules With Extended Half-Lives, Compositions And Uses Thereof |
02/28/2013 | US20130052131 Nanoparticles, methods of making nanoparticles, and methods of use |
02/28/2013 | US20130052128 Upar Binding Agents and Methods of Use Thereof |
02/28/2013 | US20130052127 Composite body for antigen or drug delivery |
02/28/2013 | DE102010039018B4 Anti-La Antikörper und ihre Anwendung zum Immunotargeting Anti-La antibodies and their application to Immunotargeting |
02/28/2013 | CA2846251A1 Anti-vcam-1 nanobodies |
02/28/2013 | CA2845946A1 Fn14-binding proteins and uses thereof |
02/28/2013 | CA2845884A1 Clostridium difficile antibodies |
02/28/2013 | CA2845872A1 Herpes simplex virus nanoemulsion vaccine |
02/28/2013 | CA2845810A1 Anti-ox40 antibodies and methods of using the same |
02/28/2013 | CA2844543A1 Microorganisms carrying a tumor antigen |
02/28/2013 | CA2844540A1 Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
02/28/2013 | CA2844538A1 Bispecific antigen binding molecules |
02/28/2013 | CA2844306A1 Anti-tie2 antibodies and uses thereof |
02/28/2013 | CA2837975A1 Bispecific t cell activating antigen binding molecules |
02/27/2013 | EP2562188A2 Compositions and methods for diagnosing and treating cancer |
02/27/2013 | EP2562187A1 Anti-CD37 antibodies |
02/27/2013 | EP2562186A1 Antigen binding proteins that bind PAR-2 |
02/27/2013 | EP2562184A1 Novel immunogenic epitopes for immunotherapy |
02/27/2013 | EP2562183A1 Novel immunogenic epitopes for immunotherapy |
02/27/2013 | EP2562182A1 Novel immunogenic epitopes for immunotherapy |
02/27/2013 | EP2561890A1 A method for producing medicaments for combatting tumors |
02/27/2013 | EP2561885A2 Use of hades as tumor suppressor target |
02/27/2013 | EP2561063A1 A vaccine comprising inactivated cells of haemophilus parasuis bacteria of serotype 5 |
02/27/2013 | EP2560994A2 Antibodies to cd122 |
02/27/2013 | EP2560990A1 Novel allergen |
02/27/2013 | EP2560989A1 Cancer-related glycopeptide epitopes, antibodies and methods of use |
02/27/2013 | EP2560691A2 Process for preparing an immunoglobulin composition |
02/27/2013 | EP2560685A2 Methods and materials for reducing liver fibrosis |
02/27/2013 | EP2560684A1 Fibronectin type iii domain-based multimeric scaffolds |
02/27/2013 | EP2560683A2 Production of heteromultimeric proteins |
02/27/2013 | EP2560682A2 Antibody preparations |
02/27/2013 | EP2560681A1 Use of tau to monitor immunotherapy |
02/27/2013 | EP2560680A2 Chimpanzee adenoviral vector-based filovirus vaccines |
02/27/2013 | EP2560679A1 Eczema treatment |
02/27/2013 | EP2560678A1 Pharmaceutical compositions |
02/27/2013 | EP2560677A1 Cold treatment |
02/27/2013 | EP2560674A2 Nanoparticle targeting to ischemia for imaging and therapy |
02/27/2013 | EP2560658A2 Methods of enhancing antibody-dependent cellular cytotoxicity |
02/27/2013 | EP2560641A2 Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
02/27/2013 | CN102947446A Prognostic method for pulmonary adenocarcinoma, pulmonary adenocarcinoma detection kit, and pharmaceutical composition for treating pulmonary adenocarcinoma |
02/27/2013 | CN102947338A Neutralizing prolactin receptor antibodies and their therapeutic use |
02/27/2013 | CN102947337A Methods for treating colorectal cancer |